Sponsor Pipeline

Endogenex, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
0
Recruiting
2
Disease Areas
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-06 NCT06267391
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in…		 Enrollment closed, study ongoing
2026-08-06 NCT06267391
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in…		 Enrollment increased: 264 -> 350 participants
2026-08-06 NCT06267391
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in…		 date change Primary completion pushed: 2026-07-01 -> 2027-02-01
2026-08-06 NCT06267391
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in…		 date change Completion pushed: 2026-10-01 -> 2027-10-01
Active Trials by Phase
Not specified
3
Active Trials
NCT IDTitleConditionStatus
Not specified
NCT07197775 Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry) Type 2 Diabetes Mellitus (T2DM) Enrolling by Invitation
NCT07197788 Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study Type 2 Diabetes Mellitus Enrolling by Invitation
NCT06267391 Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in… Type 2 Diabetes Mellitus Active, Not Recruiting
Disease Areas
Type 2 Diabetes (3) Diabetes (3)
Get alerts when Endogenex, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free